海正药业(600267) - 2023 Q1 - 季度财报
HISUNHISUN(SH:600267)2023-04-24 16:00

Financial Performance - In Q1 2023, the company's operating revenue reached CNY 3,063,534,009.22, representing a year-on-year increase of 2.90%[9] - The net profit attributable to shareholders was CNY 232,298,844.11, reflecting a significant increase of 71.91% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 169,061,721.09, up by 48.72% year-on-year[9] - Basic earnings per share increased by 72.73% to CNY 0.19, while diluted earnings per share rose by 54.55% to CNY 0.17[9] - Comprehensive income for Q1 2023 totaled ¥240,143,329.60, compared to ¥136,134,173.84 in Q1 2022, reflecting strong growth[22] - The net profit for the first quarter of 2023 was CNY 241,532,224.51, an increase from CNY 135,971,298.82 in the same period last year, representing a growth of approximately 77.6%[42] - Operating profit for the first quarter was CNY 295,762,745.82, compared to CNY 181,607,982.50 in the previous year, indicating an increase of approximately 62.8%[42] - The total profit before tax was CNY 295,646,621.49, up from CNY 183,816,282.58, marking an increase of around 60.6%[42] Cash Flow and Investments - The net cash flow from operating activities was CNY 304,464,171.32, showing a growth of 6.24% year-on-year[9] - The net cash flow from operating activities for Q1 2023 was RMB 304,464,171.32, an increase of 6.2% compared to RMB 286,573,768.25 in Q1 2022[24] - Cash inflow from investment activities totaled RMB 31,517,134.88, up from RMB 29,917,951.01 in Q1 2022[25] - The net cash flow from financing activities was RMB 47,584,427.73, a decrease of 75.6% compared to RMB 194,941,690.12 in Q1 2022[25] - The company’s net cash flow from investment activities was negative at RMB -130,004,909.59, an improvement from RMB -241,899,741.78 in Q1 2022[25] Assets and Liabilities - The total current assets as of March 31, 2023, amounted to CNY 6,742,231,451.07, an increase from CNY 6,409,130,185.76 at the end of 2022[17] - Total assets as of the end of the reporting period were ¥18,837,252,014.87, compared to ¥18,777,887,149.36 at the end of the previous period[20] - Total liabilities decreased to ¥10,259,396,669.44 from ¥10,447,695,366.55 in the previous period[20] - The equity attributable to shareholders of the listed company increased by 2.95% to RMB 8,317,395,017.99 from RMB 8,079,089,182.11 at the end of the previous year[30] Research and Development - The company continues to invest in R&D, with development expenditures reported at ¥184,430,988.46, slightly up from ¥183,719,221.12 in the previous period[20] - Research and development expenses increased to CNY 97,041,933.90 from CNY 83,286,810.37, reflecting a rise of about 16.5% year-over-year[42] Shareholder Information - The company maintained a strong shareholder base, with the largest shareholder, Zhejiang Haizheng Group Co., Ltd., holding 27.18% of the shares[49] Other Financial Metrics - The company reported a significant increase in interest income, rising to CNY 5,009,916.05 from CNY 3,601,456.79, which is an increase of approximately 38.9%[42] - The company’s tax expenses for the quarter were CNY 54,114,396.98, compared to CNY 47,844,983.76 in the previous year, reflecting an increase of about 13.4%[42] - The company’s financial expenses decreased to CNY 55,893,826.52 from CNY 74,422,505.49, a reduction of approximately 25%[42] - The investment income showed a recovery, with a profit of CNY 7,610,239.93 compared to a loss of CNY 7,286,525.19 in the previous year[42]